Objectives To examine trends in the prevalence of congenital heart defects (CHDs) in Europe and to compare these trends with the recent decrease in the prevalence of CHDs in Canada (Quebec) that was attributed to the policy of mandatory folic acid fortification.
Conclusions
The prevalence of CHDs decreased in recent years in Europe in the absence of a policy for mandatory folic acid fortification. One possible explanation for this decrease may be an as-yet-undocumented increase in folic acid intake of women in Europe following recommendations for folic acid supplementation and/or voluntary fortification. However, alternative hypotheses, including reductions in risk factors of CHDs (eg, maternal smoking) and improved management of maternal chronic health conditions (eg, diabetes), must also be considered for explaining the observed decrease in the prevalence of CHDs in Europe or elsewhere.
(J Pediatr 2012;-:---).
T he prevalence of congenital heart defects (CHDs) is known to vary across populations and over time. 1, 2 These variations are at least in part due to data issues such as completeness of the (prenatal and postnatal) diagnosis and/or registration of cases, whether pregnancy terminations are included, which (minor) anomalies are excluded, and the duration of ascertainment, among other issues.
Recently, 2 reports, 3, 4 based on a study of trends in CHDs in Quebec, Canada, showed an increase in the live birth prevalence of severe CHDs in the early and middle 1990s, followed by a downward trend beginning in 1998. The authors attributed this downward trend to the implementation of folic acid fortification of food staples in Canada in 1998.
In Europe, although many countries have issued various recommendations regarding folic acid supplementation for women of reproductive age, or specifically for those who intend to become pregnant, mandatory fortification programs do Medical Faculty, Otto-van-Guericke University, Magdeburg, Germany; 27 not yet exist. Moreover, previous studies have shown that in the past, these recommendations have not had an appreciable effect on the prevalence of neural tube defects (NTDs) in European countries. 5 It is also worth noting that the currently available evidence is much stronger for the efficacy of folic acid for the prevention of NTDs than for the prevention of CHDs. 6, 7 In Europe, most population-based congenital anomaly registries are part of the European Surveillance of Congenital Anomalies (EUROCAT, http://www.eurocat-network.eu/), with a common database. Each year, EUROCAT performs statistical monitoring for trends and clusters in time. 8 In 2009, EUROCAT published a special report on CHDs, 9, 10 partly in response to the World Health Organization Global Burden of Disease project. Based on some of the analyses for this report, a general decrease in CHDs was signaled and an additional pooled analysis of "severe" CHDs 11 provided preliminary evidence of a similar decrease to that in Quebec.
Given this background, and in particular given the difference between European countries and Canada in the policy for fortification of food staples with folic acid, we thought that it would be interesting to compare in more detail the trends in the prevalence of CHDs in Europe with those reported for Quebec. Hence, in this study, we examined trends in total and live birth prevalence of CHDs using data for >47 000 cases of CHD in EUROCAT registries. We estimated the trends for both all CHD combined and separately for 3 severity groupings of CHDs.
Methods
Since 1980, the EUROCAT central database has held individual anonymous records of cases of congenital anomaly occurring in the registry population, including live births, fetal deaths from 20 weeks' gestation, and terminations of pregnancy for fetal anomaly. Information on each of the registries, including their methods of case ascertainment and local procedures regarding ethics approval for the registries' activities and their collaborations with EUROCAT, are available elsewhere 12 and on the EUROCAT Web site (http://www.eurocat-network.eu/ABOUTUS/Member Registries/MembersAndRegistryDescriptions/AllMembers). All registries use the International Classification of Diseases (ICD)-9 or -10 with British Paediatric Association extension to code up to 9 syndrome or malformation codes for each case.
For the current study, all cases with a code for CHD were extracted from the EUROCAT database for the same 29 population-based registries in 16 countries that were included in the EUROCAT CHD Special Report 9 covering nearly 7.3 million births, 1990-2007 (Table I) . Only registries with recent data (at least up to birth year 2004) and good ascertainment based on EUROCAT data quality indicators (>75% of EUROCAT average major congenital anomaly prevalence and more than half the EUROCAT average prevalence of selected severe CHDs [http://www. eurocat-network.eu/content/DQI-Introduction-May-2008. pdf]) were included. In practice, the participating registries had much higher thresholds for the EUROCAT data quality indicators than the a priori minimum values that had been set for participation in the study.
The ICD codes defining CHDs were Q20-26 (ICD-10) and 745, 746, 7470-7474 (ICD-9-British Paediatric Association). Minor cases of CHDs were excluded as per the EUROCAT list of minor anomalies for exclusion (http://www.eurocatnetwork.eu/content/EUROCAT-Guide-1.3.pdf), in particular patent ductus arteriosus among preterm babies. Cases of CHD and a chromosomal anomaly were also excluded from analysis.
We plotted the time trends, during the period 1990-2007, in the total and live birth prevalences of all nonchromosomal CHDs, as well as 3 severity groupings of nonchromosomal CHDs using the EUROCAT classification of the severity of CHDs, 9 which was based on relative perinatal mortality. These severity groupings were defined as follows: (1) severity group I: single ventricle, hypoplastic left heart syndrome, hypoplastic right heart syndrome, Ebstein anomaly, tricuspid atresia; (2) severity group II: pulmonary valve atresia, common arterial truncus, atrioventricular septal defects, aortic valve atresia/stenosis, transposition of great vessels, tetralogy of Fallot, total anomalous pulmonary venous return, coarctation of aorta; excluding cases with coexisting severity I CHD anomalies; and (3) severity group III: ventricular septal defect, atrial septal defect (ASD), pulmonary valve stenosis; excluding cases with coexisting severity I or severity II CHD anomalies.
Altogether, these 3 severity groups accounted for 90% of all cases of CHD ( Table I) . Severity group I accounted for 7%, severity group II for 20%, and severity group III for 60% of all cases. Of the cases, 10%, including those with patent ductus arteriosus in term infants and a few other CHDs, were not included in any of the 3 EUROCAT severity groups for CHDs. 9 Total prevalence of CHD was defined as the total number of cases of CHD (live births plus fetal deaths after 20 weeks of gestation plus terminations of pregnancy for fetal anomaly) per 10 000 total births (live births plus fetal deaths). Live birth prevalence was defined as the number of live births with CHD per 10 000 live births.
We examined the plots of time trends in total and live birth prevalence of CHDs using restricted cubic splines, [13] [14] [15] which can provide a flexible, semiparametric, continuous model of the relation between prevalence of CHD and time.
Using the number of births as the "exposure" variable, we then used random-effects Poisson regression models to examine the annual trends in the prevalence of CHDs, for all CHDs combined and for the 3 severity groups of CHDs. Random-effects models were used to take into account heterogeneity that may exist across the registries 16 (http:// www.eurocat-network.eu/content/DQI-Introduction-May-2008.pdf).
We excluded from our analyses of trends with Poisson models cases with isolated ASDs. This was done because the registration of the latter is likely to vary over time because THE JOURNAL OF PEDIATRICS www.jpeds.com Vol. -, No. -of diagnostic or reporting issues (notably problems related to distinguishing patent forman ovale from a true ASD). In addition, the EUROCAT instructions for coding and registration of ASDs changed recently regarding the exclusion of patent or persistent foramen ovale (http://www.eurocatnetwork.eu/content/EUROCAT-Guide-1.3.pdf) and subsequently a smaller number of ASD were reported by registries. This can in turn result in a lower prevalence of CHDs, in particular for severity group III CHDs, as this group includes isolated ASD. Hence, to avoid such bias in our trends, we excluded from the statistical analysis of trends cases with isolated ASD (N = 7728).
In the Poisson models, we used different splines (or "piece-wise exponential models") for modeling the time trends in the prevalence of CHDs; splines with different knots were used to analyze the annual trends in prevalence with (1) a single knot at 1998 to allow separate analysis of trends ("slopes" corresponding to annual trends) before and after 1998 in order to compare trends for EUROCAT registries with those reported in the studies using the data for Quebec articles 3, 4 ; (2) All analyses were performed using Stata software (version 10; StataCorp, College Station, Texas). Figure 2 and Tables III and IV ( Figure 2 and Table IV ; available at www.jpeds.com) show the time trends for the total prevalence of CHDs for the 3 severity groupings (in order of severity) of CHDs. In general, the trends, including the inflection points and rates of change over time, varied for the different severity groups. For severity group I, the total prevalence of CHD was relatively stable at 5 per 10 000. For severity group II ( Figure 2 and Table III), the total prevalence clearly increased until about 2000 with an annual increase of 4% (annual PR 1.04, 95% CI, 1.03-1.05) and decreased thereafter, particularly after 2004, with an annual decrease of 5% per year (annual PR 0.95, 95% CI, 0.92-0.99).
Results
For severity group III ( Figure 2 and Table IV), the most prevalent group, the trends were similar to those observed for all CHD combined. The total prevalence of severity group III CHD increased by 4% per year between 1990 and 1994 (annual PR 1.04, 95% CI, 1.02-1.06), with a small increase thereafter until 2004. Subsequently, there was a reversal of this trend with a decrease of 4% per year in the total prevalence of CHD in severity group III between 2004 and 2007 (annual PR 0.96, 95% CI, 0.94-0.98). Figure 3 (available at www.jpeds.com) and Tables III and IV show the time trends for live birth prevalence of CHD during the study period. In general, the trends in live birth prevalence were similar to those noted here earlier for the total prevalence of CHDs, except for severity group I (the most severe group), for which the annual live birth prevalence of CHDs decreased between 1994 and 2004 and was essentially stable thereafter (Table III) .
Discussion
Based on data on more than 47 000 case of CHD from 29 population-based registries in Europe during the period 1990 to 2007, we found that the total prevalence of CHD in THE JOURNAL OF PEDIATRICS www.jpeds.com
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Given essentially no time trend in the total prevalence for this group, this decreasing trend in the live birth prevalence for severity group I is most likely explained by the increase in prenatal diagnosis and termination of pregnancy for the most severe CHDs. 9, 10, 17, 18 In any case, trends in total prevalence as noted here are likely to be the most relevant indicator of any effects that one may attribute to specific exposures, including any protective effects related to folic acid.
In Quebec, Ionescu-Ittu et al 3 found an increase in the live birth prevalence of severe CHDs (a group corresponding roughly to our severity groups I and II but including chromosomal syndromes) before 1998 (when fortification of food staples began in Canada) and a decrease after 1998, a decrease that started earlier than in Europe. The authors attributed this decrease to the implementation of the folic acid fortification program in Canada. Subgroup analysis found that the main decrease was in the group of severe conotruncal defects. In our study, we found a similar increase in both the total and live birth prevalence of nonchromosomal CHDs, excluding patent ductus arteriosus and ASDs, in the 1990s (and early 2000s) and a decrease beginning in 2004. We found that the decrease was in severity groups II and III (the latter was not analyzed in Quebec). Severity group II corresponds most closely with the severe conotruncal defects, including tetralogy of Fallot, analyzed in the study by Ionescu-Ittu et al. 3 The observed decrease in our data cannot be due to mandatory fortification of food staples as such a policy has not yet been implemented in European countries. 19 Hence, alternative explanations must be considered for this decrease. One possible explanation is an increase in folic acid intake due to either voluntary fortification, [19] [20] [21] as has been shown to be the case in Ireland, and/or the various recommendations issued for folic acid supplementation for women of reproductive age in European countries. Nevertheless, up to 2004, these recommendations did not have an appreciable effect on the prevalence of NTDs in European countries. 5 Data on trends in folic acid intake or blood folate levels are not currently available for Europe (other than the Irish data cited earlier) to confirm or refute a possible role for folic acid in the observed decrease in the prevalence of CHDs in recent years.
If the observed decrease in the prevalence of CHDs in Europe is indeed at least in part due to increases in folic acid intake of women, this may have occurred as a result of more recent increases in folic acid intake that were not yet present in the population at the time previous studies were conducted. This hypothesis is consistent with the observation that the decreasing trends in CHDs in our data were mostly limited to the most recent period of [2004] [2005] [2006] [2007] . The most recent analysis of NTD data in EUROCAT registries has also pointed to a small decrease in NTDs after 2004. 11, 19, 22 Another possibility is that the impact of folic acid on CHDs may have a different profile in terms of the required dose and timing of folic acid intake compared with those of NTDs; the latter requires in particular an adequate periconceptional intake of folic acid. If the intake of folic acid at later times (not in the periconceptional period but still sufficiently early in pregnancy before or at the beginning of the period of organogenesis) is at least somewhat more effective for CHDs (period of organogenesis 3-8 weeks) than for NTDs (period of organogenesis first 3 weeks), one could observe trends in CHDs as a result of increases in folic acid intake that may not have an appreciable impact on the prevalence of NTDs. In particular, women may be more likely to start taking folic acid supplements after conception rather than preconceptionally.
Alternative hypotheses, including reductions in risk factors of CHDs (eg, maternal smoking [23] [24] [25] ) and improved management of maternal chronic health conditions (eg, diabetes 26, 27 ) must also be considered for explaining the observed decrease in the prevalence of CHDs in Europe or elsewhere.
Registration issues or other data artifacts are unlikely to explain the decrease in CHDs in recent years in our data. However, an increase in prenatal and postnatal diagnoses of CHDs may be the most plausible explanation for the increases in the prevalence of CHDs observed in the 1990s in both our data and in those from Quebec, 3 although the possibility of an environmental cause, especially in relation to the increase in severe CHDs, should not be totally discounted.
The observed differential trends in prevalence of CHDs by severity in our data have at least 2 possible explanations. The fact that we found no increase in CHDs for the most severe group but a significant increase for the less severe groups in the 1990s is likely to be at least in part explained by improvements in prenatal and postnatal detection and hence more complete registration of CHDs, particularly for the CHDs included in severity groups II and III.
The decreases we found in the prevalence of CHDs for severity groups II and III in the latter part of the study period (2004) (2005) (2006) (2007) are unlikely to be due to changes in diagnosis and/or registration of cases. We have no reason to believe that the diagnosis and/or registration of cases became less complete in our data in recent years. There may have been a small number of late diagnoses, particularly for CHDs in severity group III, that were not yet registered in the 2007 data. However, these cases would have presumably had a minor impact on the overall EUROCAT trends during the latter part of the study period. Moreover, the decreases we found were not limited to 2007 data but also occurred in the prevalence of CHDs between 2004, 2005, and 2006. The differential trends we observed across the severity groups, particularly the decreases observed for severity groups II and III but not for severity group I, may be due to differential effects of folic acid (or other etiologic factors) on different CHD anomalies, 6 although this needs to be investigated further.
At this time, we cannot confirm or refute a possible role for folic acid in the decrease in the prevalence of CHDs in Europe. Alternative hypotheses for this decrease include reductions in risk factors of CHDs (eg, maternal smoking [23] [24] [25] ) and improved management of maternal chronic health conditions (eg, diabetes 26, 27 ). The observed decrease in the prevalence of CHDs is to be welcomed, but better understanding of its causes might allow public health measures to be taken to ensure it is maximized and experienced by all sectors of the population. n Submitted for publication Oct 10, 2011 A, severity group I, B, severity group II, and C, severity group III. Trends were estimated using restricted cubic splines.
